

July 19, 2017

To,
Dy. General Manager
Department of Corporate Services,
BSE Ltd.,
P. J. Towers, Dalal Street,
Fort, Mumbai – 400 001.

Ref: Scrip Code: 532296

To,
The Manager – Listing,
The National Stock Exchange of India Ltd.,
Plot No. C/1, G Block,
Bandra Kurla Complex,
Bandra (E), Mumbai – 400 051.

Ref: Scrip Name: GLENMARK

Dear Sirs,

**Sub:- Glenmark Pharmaceuticals Enters Exclusive Agreement with Cyndea Pharma S.L.
for Generic Soft-Gelatin Capsule Drug Products**

With reference to the subject mentioned above, kindly find attached media release which is self-explanatory.

Request you to kindly take the same on record.

Thanking you,

Yours faithfully,
For Glenmark Pharmaceuticals Ltd.



Harish Kuber
Company Secretary & Compliance Officer

Press Release

For Immediate Release

Glenmark Pharmaceuticals Enters Exclusive Agreement with Cyndea Pharma S.L. for Generic Soft-Gelatin Capsule Drug Products

Under the Agreement, Glenmark and Cyndea will Partner to Develop, License, Manufacture and Supply for Commercialization Generic Soft-Gelatin Capsule Drug Products

Expanded Dosage Form Capabilities Enriches Glenmark's Growing Pipeline and Solidifies Industry Leadership in Complex Generics

Mumbai, India; July 19, 2017: Glenmark Pharmaceuticals, a global pharmaceutical company, announced today it has entered into a development, license, manufacture and commercial supply agreement with Cyndea Pharma S.L., granting exclusive rights to use their technology for developing generic, soft-gelatin capsule formulations of certain pharmaceutical products.

"As many as 70 percent of small molecule pharmaceuticals are difficult for the body to absorb, which leads to challenges in developing effective oral formulations for these medicines,"¹ said Robert Matsuk, President, North America, Global API at Glenmark Pharmaceuticals. "Because of these challenges, the use of soft-gelatin capsules have wide applications to improve absorption and bioavailability of these medicines. Accessing this formulation and manufacturing technology with our strategic partner Cyndea will support Glenmark's continued mission of providing important and cost-effective generic medicines to patients."

Under this agreement, Glenmark receives exclusive rights to the United States and Canada markets for these soft-gelatin formulations in exchange for sharing development costs and profits from future sales. In addition, the agreement provides for the companies to add further soft-gelatin product candidates for development and commercialization, as new branded, soft-gelatin, capsule-based drug products become available in the marketplace.

"Glenmark is an ideal partner to expand our soft-gelatin technology into much needed therapeutic categories and markets," said Gonzalo Ballesteros, Managing Director of Cyndea. "Cyndea has made significant financial investments in both its new Madrid-based research and development facility and state-of-the-art production facility located in Soria, Spain. Cyndea is a global, market-leading supplier of generic, prescription, soft-gelatin capsules in the world and our partnership with Glenmark provides expanded access into North America."

¹ "Bioavailability & Solubility." *Drug Development & Delivery*. March 2015. <http://www.drug-dev.com/Main/Back-Issues/SPECIAL-FEATURE-Bioavailability-Solubility-A-Deman-875.aspx>. Last accessed June 21, 2017

About Cyndea Pharma

Cyndea Pharma specializes in the development and manufacturing of Women's Health Care and niche products using differentiated technologies to deliver value added products to its customers. Since 2012, it has established itself as one of the leading soft-gelatin developers and manufacturers in the world, supporting its partners in more than 90 countries.

About Glenmark Pharmaceuticals

Glenmark Pharmaceuticals Ltd. (GPL) is a research-driven, global, integrated pharmaceutical organization headquartered at Mumbai, India. It is ranked among the top 75² Pharma & Biotech companies of the world in terms of revenue. Glenmark is a leading player in the discovery of new molecules both NCEs (new chemical entity) and NBEs (new biological entity). Glenmark has several molecules in various stages of clinical development and is primarily focused in the areas of oncology, dermatology and respiratory.

The company has a significant presence in the branded generics markets across emerging economies including India. Glenmark along with its subsidiary has 17 manufacturing facilities across five countries and has six R&D centers. The Generics business of Glenmark services the requirements of the US and Western European markets. The API business sells its products in over 80 countries, including the US, various countries in the EU, South America and India.

² SCRIP Ranking 2017